



## **NuSirt Biopharma to Present at American Diabetes Association's 75th Scientific Sessions**

*Poster presentations to explore potential of company's technology in the treatment of Type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and review emerging research related to high cholesterol*

**Nashville, Tenn. (May 18, 2015)** – [NuSirt Biopharma](#), a company dedicated to improving the lives of those with chronic metabolic diseases, will present three posters featuring its technology at the [American Diabetes Association's 75<sup>th</sup> Scientific Sessions](#). The event, which brings together diabetes researchers and clinicians from more than 120 countries, will be held June 5-9, 2015, at the Boston Convention and Exhibition Center in Boston, Mass.

NuSirt's technology combines leucine, a naturally occurring amino acid, with existing pharmaceuticals. Posters the company will present at the Scientific Sessions involve research investigating its technology's potential to treat conditions such as Type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Emerging research regarding its ability to treat high cholesterol also will be presented.

Details of the poster presentations are as follows:

- **Leucine-Metformin Synergy Activates the AMPK/Sirt1 Pathway to Increase Insulin Sensitivity in Skeletal Muscle and Glucose and Lipid Metabolism and Lifespan in *C. elegans***
  - Abstract Number: 1237-P
  - Date and Time: Sunday, June 7, 2015, from 12:00 - 2:00pm
  - Location: Hall B
  
- **Leucine Synergizes with Phosphodiesterase 5 (PDE5) Inhibitors and Metformin to Reverse Hepatic Lipid Accumulation and Inflammation and Treat Non-alcoholic Fatty Liver Disease (NAFLD)**
  - Abstract Number: 260-LB
  - Date and Time: Sunday, June 7, 2015, from 12:00 - 2:00pm
  - Location: Hall B
  
- **Leucine Amplifies the Effects of Nicotinic Acid on Hyperlipidemia and Atherosclerosis in LDLRKO-Mice**
  - Abstract Number: 524-P
  - Date and Time: Monday, June 8, 2015, from 12:00 - 2:00pm
  - Location: Hall B

### **About Diabetes**

Diabetes is the [seventh](#) leading cause of death in the U.S., and its complications include blindness, kidney failure and peripheral amputation. According to the American Diabetes Association, more than 29 million Americans have diabetes, and an additional 86 million Americans age 20 and older have prediabetes.

### **About Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)**

Non-alcoholic fatty liver disease (NAFLD) is a result of fat building up in the liver, preventing the organ's ability to remove toxins from blood. It affects [up to one-third](#) of the general population. Although there are no known causes for NAFLD, obesity, high cholesterol, diabetes and high blood pressure are all considered risk factors.

Non-alcoholic steatohepatitis (NASH) occurs in [10 to 30 percent](#) of those with NAFLD. It happens when the liver of a person with NAFLD becomes inflamed, causing severe liver cell damage. Over time, this can result in permanent scarring and hardening of the liver, which leads to cirrhosis. The consequences of cirrhosis include muscle wasting, fluid retention, intestinal bleeding, and liver failure.

### **About NuSirt Biopharma**

NuSirt Sciences, Inc., headquartered in Nashville, is dedicated to improving the lives of people living with chronic metabolic diseases. The company has a unique technology platform that uses a patented combination of leucine, an essential amino acid, and existing human medicines targeted at diseases that may be addressed by activating sirtuin pathways. In pre-clinical studies, these combinations have shown promise in preventing and treating metabolic diseases and enhancing the effectiveness of existing pharmaceuticals. For more information, please visit [www.nusirt.com](http://www.nusirt.com).

###

### **Contact:**

Nicole Cottrill

615-327-7999

[ncottrill@seigenthaler.com](mailto:ncottrill@seigenthaler.com)